290 related articles for article (PubMed ID: 34817191)
1. Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study.
Rong D; He B; Tang W; Xie S; Kuang S; Grazioli L; Hussain SM; Yang Y; Wang J
AJR Am J Roentgenol; 2022 Apr; 218(4):687-698. PubMed ID: 34817191
[No Abstract] [Full Text] [Related]
2. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma.
Allen BC; Ho LM; Jaffe TA; Miller CM; Mazurowski MA; Bashir MR
AJR Am J Roentgenol; 2018 Jun; 210(6):1266-1272. PubMed ID: 29629800
[TBL] [Abstract][Full Text] [Related]
3. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.
Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J
Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766
[TBL] [Abstract][Full Text] [Related]
4. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
[TBL] [Abstract][Full Text] [Related]
5. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
[TBL] [Abstract][Full Text] [Related]
6. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine.
Stocker D; Hectors S; Bane O; Vietti-Violi N; Said D; Kennedy P; Cuevas J; Cunha GM; Sirlin CB; Fowler KJ; Lewis S; Taouli B
Eur Radiol; 2021 Dec; 31(12):9306-9315. PubMed ID: 34043055
[TBL] [Abstract][Full Text] [Related]
8. LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement.
Vernuccio F; Cannella R; Meyer M; Choudhoury KR; Gonzáles F; Schwartz FR; Gupta RT; Bashir MR; Furlan A; Marin D
AJR Am J Roentgenol; 2019 Aug; 213(2):W57-W65. PubMed ID: 31039012
[No Abstract] [Full Text] [Related]
9. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
Kim YY; An C; Kim S; Kim MJ
Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.
Choi SH; Lee JM; Yu NC; Suh KS; Jang JJ; Kim SH; Choi BI
AJR Am J Roentgenol; 2008 Aug; 191(2):529-36. PubMed ID: 18647927
[TBL] [Abstract][Full Text] [Related]
12. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
[No Abstract] [Full Text] [Related]
13. Liver Imaging Reporting and Data System version 2018 category 5 for diagnosing hepatocellular carcinoma: an updated meta-analysis.
Lee S; Kim YY; Shin J; Roh YH; Choi JY; Chernyak V; Sirlin CB
Eur Radiol; 2024 Mar; 34(3):1502-1514. PubMed ID: 37656177
[TBL] [Abstract][Full Text] [Related]
14. Detection of liver metastases on gadobenate dimeglumine-enhanced MRI: systematic review, meta-analysis, and similarities with gadoxetate-enhanced MRI.
Zhang L; Yu X; Huo L; Lu L; Pan X; Jia N; Fan X; Morana G; Grazioli L; Schneider G
Eur Radiol; 2019 Oct; 29(10):5205-5216. PubMed ID: 30915560
[TBL] [Abstract][Full Text] [Related]
15. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
[TBL] [Abstract][Full Text] [Related]
17. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma.
Kierans AS; Makkar J; Guniganti P; Cornman-Homonoff J; Lee MJ; Pittman M; Askin G; Hecht EM
J Magn Reson Imaging; 2019 Jun; 49(7):e205-e215. PubMed ID: 30257054
[TBL] [Abstract][Full Text] [Related]
18. Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent.
Kim SY; Wu EH; Park SH; Wang ZJ; Hope TA; Yee J; Zhao LQ; Chang WC; Yeh BM
Abdom Radiol (NY); 2016 Aug; 41(8):1522-31. PubMed ID: 26971341
[TBL] [Abstract][Full Text] [Related]
19. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
Jeon TY; Kim SH; Lee WJ; Lim HK
Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
[TBL] [Abstract][Full Text] [Related]
20. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.
Ding F; Huang M; Ren P; Zhang J; Lin Z; Sun Y; Liang C; Zhao X
Eur Radiol; 2024 Apr; 34(4):2445-2456. PubMed ID: 37691080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
